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Abstract The Dbl family proto-oncogene vav is a guanine
nucleotide exchange factor (GEF) for Rho family GTPases.
Deletion of the N-terminus of Vav, harboring the single calponin
homology (CH) domain, activates Vav’s transforming potential,
suggesting an important role of the CH domain in influencing
Vav function. Since calponin binds actin, it has been suggested
that the CH domain may mediate association with the actin
cytoskeleton. In this study we have analyzed the subcellular
localization and investigated the putative actin association of the
Vav protein using enhanced green fluorescent protein (EGFP)
fusion constructs. Our data show that both EGFP-tagged full
length Vav and the CH domain-depleted EGFPvav 143^845
construct localize throughout the cytoplasm but fail to colocalize
with F-actin. However, the latter construct of Vav was more
strongly retained in the Triton-insoluble cytoskeleton fraction
than full length Vav. Whereas removal of the CH domain had no
apparent influence on the subcellular localization of Vav, deletion
of the SH domains caused nuclear localization, indicating that
Vav contains a functional nuclear localization signal. Expression
of N-terminally truncated Vav constructs caused depolarization
of fibroblasts and triggered the bundling of actin stress fibers into
parallel arrays in NIH 3T3 cells. Notably, the parallel actin
bundles showed prolonged resistance to the actin polymerization
antagonists cytochalasin B and latrunculin B. These data point
towards a regulatory role for the CH domain in Vav and suggest
an actin cross-linking or bundling protein as a downstream
effector molecule of vav-mediated signalling pathways.
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1. Introduction
Rearrangement of the actin cytoskeleton is largely in£u-
enced by the activity of Rho family GTPases, namely Rac1,
RhoA and Cdc42, leading to the formation of lamellipodia,
stress ¢bers, and ¢lopodia, respectively [1,2]. Upstream regu-
lators control their nucleotide-bound state by activating the
GTPase activity (GAPs) or by facilitating the exchange of
GDP for GTP (GEFs). Some of these proteins, like Dbl [3]
and Vav [4], exhibit transforming activities, presumably by
constitutively activating Rho family GTPases. It is still un-
clear whether Vav, which is speci¢cally expressed in cells of
the hematopoietic system, acts as a speci¢c GEF for Rac1
[5,6], or enhances nucleotide exchange for all three Rho family
GTPases [7,8]. Like all known GEFs Vav consists of an ar-
rangement of functional modules [9,10] containing an active
core comprising a Dbl homology (DH) domain and an adja-
cent pleckstrin homology (PH) domain [10^13]. Additional C-
and N-terminal domains in the various Dbl family proteins
are likely to modulate the speci¢city of the molecule for cer-
tain GTPases by serving as targeting modules or regulators of
protein-protein or protein-phospholipid interactions (reviewed
in [10,14]).
A module unique to two GTPase regulators, the Cdc42
GAP, IQGAP, and the Rac1 GEF, Vav, is the calponin ho-
mology (CH) domain [15]. This 100 residue motif has been
proposed to serve as an autonomous actin binding site, di-
rectly linking signalling molecules to the actin cytoskeleton.
Notably, the ¢rst 216 amino acid residues of IQGAP1, em-
bracing the CH domain, have been demonstrated to co-sedi-
ment with actin in vitro [16]. However, isolated CH domains
from other single CH domain-containing proteins [17] fail to
bind to actin, suggesting a subordinate role for this motif in
actin binding. Moreover, in the archetypal smooth muscle
protein calponin this domain is neither necessary nor su⁄-
cient, and indeed dispensable for actin association in vitro
and in vivo [18]. In this context, the role of the single CH
domain in Vav required reconsideration (see [19] for review).
With the exception of gelsolin [20] and co¢lin [21,22] little is
known about the ultimate downstream e¡ectors of Rho family
GTPase signal cascades which directly interact with the actin
cytoskeleton (see [23,24]). It is evident that GTPases them-
selves cannot modulate the conformation of actin ¢laments,
but rather mobilize actin binding proteins to specialized sites
within the cell, which then drive actin polymerization in la-
mellipodial protrusions, or lead to the stabilization of actin
bundles in stress ¢bers [25^27]. It is thus important to deter-
mine the cellular localization of components within the signal-
ling pathway of small GTPases involved in actin cytoskeleton
rearrangements and their immediate upstream and down-
stream e¡ector molecules (see [19]).
Here, using enhanced green £uorescent protein (EGFP)-
tagged mutant constructs we show that the CH domain is
not a critical determinant for the cellular localization of Vav
and that deletion of the CH domain-containing amino-termi-
nus enhances the formation of Rho-dependent stress ¢bers in
NIH 3T3 cells.
2. Materials and methods
2.1. EGFPvav constructs
Full length human proto-vav (1^845) and vav 143^595 [28,29] in
pTag/CMV-neo were a gift of G. Baier (University of Innsbruck). For
both constructs the insert (including the N-terminal p18HIV tag en-
coded by the vector) was cut out with BamHI and BclI and cloned
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into the BamHI site of pMW172 [30]. The correct orientation was
con¢rmed by sequencing using a LI-Cor model 4000 automated se-
quencer (MWG-Biotech, Germany). Both pMW172 constructs were
digested with PstI, which cuts once in the vav sequence and once in
the ampicillin resistance gene of the vector. To obtain vav 1^595 the
fragment of vav 1^845 pMW172 encoding the N-terminal part of vav
was ligated to the fragment of vav 143^595 pMW172 encoding the C-
terminal part. For vav 143^845 the C-terminal fragment of vav 1^845
pMW172 was ligated to the N-terminal fragment of vav 143^845.
Inserts of all four vav constructs in pMW172 were cut out with Bam-
HI and EcoRI and cloned in frame into the BglII and EcoRI sites of
pEGFP-C1 (Clontech). All constructs were con¢rmed by sequencing
the region of the restriction sites used. EGFPvav 1^143 was generated
by the polymerase chain reaction (PCR) using EGFPvav 1^595 as
template. A sense primer (GAG AGG ATC CAT GGG ATC CCG
TAT CCA G) binding to the N-terminus of the p18HIV tag introduc-
ing a BamHI site at its 5P end and an antisense primer (CTG AAT
TCA CTG TAG ATG TCT TCA TC) binding to the region coding
for vav 138^143 and introducing an EcoRI site at its 5P end were used.
The isolated PCR product was digested with BamHI and EcoRI and
ligated into the BglII and EcoRI site of pEGFP-C1. The stop codon
supplied by the vector was used to terminate translation. The correct
sequence was con¢rmed by sequencing both strands. To express a
fusion protein of the CH domain of calponin h1 to EGFP a PCR
was performed with calponin h1 1^127 in pCGN [18] as template
using primers as follows: sense primer (GAG GAT CCA GCT
ACC CTT ATG ACG TG) binding to the N-terminus of the HA
tag encoded by pCGN and introducing a BamHI site at its 5P end;
antisense primer (GAG AAT TCT TAC AGA GCC AGG AGA
GTG) binding to the region encoding amino acids 122^127 introduc-
ing a stop codon and an EcoRI site. The PCR product was cloned and
sequenced as for EGFPvav 1^143.
2.2. Cell culture, transfection and immuno£uorescence microscopy
NIH 3T3 or REF 52 ¢broblasts [31] were grown in high glucose
(4500 mg/l) DMEM supplemented with 10% FBS (Hyclone, Utah,
USA), penicillin/streptomycin (Life Technologies, Austria) at 37‡C
and 5% CO2. Cells at 70% con£uence were transfected using the Lip-
ofectamine (Life Technologies, Austria) method in the absence (NIH
3T3) or presence (REF 52) of serum, essentially as described [18].
Stable cell lines were passaged after similar transfection times and
cells resistant to 1 mg/ml G-418 and expressing the transfected trans-
gene were identi¢ed by Western blotting. For transient expression
cells were grown and transfected as described [31] and prepared for
either immuno£uorescence or protein extraction 24 h post transfec-
tion. For immuno£uorescence microscopy cells were cultured on 15
mm glass coverslips. Cells were washed three times in PBS (138 mM
NaCl, 26 mM KCl, 84 mM Na2HPO4, 14 mM KH2PO4, pH 7.4),
¢xed in 3.7% PFA (Merck, Germany) in PBS for 60 min and sub-
sequently extracted with 0.3% Triton X-100 in PBS for 1 min. F-actin
was visualized using Alexa 568 or Alexa 488 phalloidin (Molecular
Probes, The Netherlands). Antibodies to GFP (polyclonal and mono-
clonal) were from Clontech, polyclonal antibodies to vav from Santa
Cruz Biotechnology, and horseradish peroxidase-coupled secondary
antibodies from Amersham. Fluorescent images were recorded on a
Zeiss Axiophot using a 63U oil immersion lens and Kodak P3200 or
P400 Tmax ¢lm.
2.3. Cell extraction and fractionation
Twenty-four hours after transfection cells grown in 60 mm petri
dishes were washed twice with ice-cold PBS and extracted with 200
Wl extraction bu¡er (10 mM HEPES pH 7.5, 1.5 mM MgCl2, 1 mM
DTE, 0.1 mM PMSF, 0.67 Wg/ml pepstatin, 1.67 Wg/ml leupeptin, 10
or 100 mM KCl, with or without addition of 0.5% Triton X-100).
Cells were scraped o¡ with a cell scraper, transferred to a glass ho-
mogenizer and lysed with 40 strokes on ice. The extract was centri-
fuged at 100 000Ug for 30 min at 4‡C in a Sorvall S100-AT4 rotor.
The supernatant was centrifuged again at 100 000Ug for 20 min. To
the supernatant of this latter centrifugation 1/4 volume of 5USDS
sample bu¡er was added. The pellet of the ¢rst centrifugation was
washed with 200 Wl of extraction bu¡er and centrifuged again at
100 000Ug for 20 min at 4‡C. The supernatant was removed and
the pellet was brought to the original volume and 1/4 volume of
5USDS sample bu¡er was added. The distribution of EGFPvav in
the pellet and supernatant was estimated by Western blotting using a
monoclonal antibody against GFP.
2.4. Electrophoresis and Western blotting
Analytical SDS gel electrophoresis on 8^22% gradient polyacryl-
amide mini-slab gels and Western blotting onto nitrocellulose
(Amersham) was performed as described elsewhere [32]. Transferred
proteins were visualized using horseradish peroxidase-coupled second-
ary antibodies and the ECL chemiluminescence detection system
(Amersham).
2.5. Cytoskeleton disruption
Cells grown on 15 mm glass coverslips to 60% con£uence, serum-
starved for 24 h and then incubated for 30 min with 5 WM cytocha-
lasin B or 200 nM latrunculin B (Santa Cruz Biotechnology, USA) in
DMEM. Cells were then processed for £uorescence microscopy as
above.
3. Results
For the purpose of this study we constructed Vav mutants
(Fig. 1A), fused at their amino-terminal ends to the EGFP
lacking either the amino-terminus embracing the CH domain
(EGFPvav 143^845), the entire SH2-SH3-SH2 domain region
at the carboxy-terminal end (EGFPvav 1^595), or both
(EGFPvav 143^595). For comparison of the cellular e¡ects
of these mutants we used the full length Vav molecule (EGFP-
vav 1^845) and the isolated amino-terminus (EGFPvav 1^
143). With the exception of the latter construct, all EGFP
fusion constructs contained the catalytic core consisting of
the DH and PH domains, the cysteine-rich, diacylglycerol-
Fig. 1. A: Molecular domain structure of EGFPvav constructs. Ab-
breviations: CH, calponin homology domain; AC, acidic domain;
DH, Dbl homology domain; PH, pleckstrin homology domain; CR,
cysteine-rich region, SH2/SH3, src homology domains 2 and 3. The
position of the two putative nuclear localization signals is indicated.
All EGFP fusions contain the £uorescent protein at their amino-ter-
minus. Numbers indicate amino acid residues according to the se-
quence of human vav. B: Western blot of whole cell extracts from
stable cell lines expressing the indicated EGFPvav constructs, or
transiently transfected NIH 3T3 cells (EGFPvav 1^143) probed with
a polyclonal anti-GFP antibody.
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binding region, as well as the two putative nuclear localization
signals (NLS).
Con£icting reports by several groups have shown either
cytoplasmic [8,33] or nuclear localization for Vav [34]. To
determine the subcellular localization of Vav we selected sta-
ble cell lines from NIH 3T3 ¢broblasts transfected with the
EGFP-tagged fusion constructs depicted in Fig. 1A. Expres-
sion of the transgene in selected stable cell lines was veri¢ed
by Western blotting using a polyclonal antibody against GFP
or human Vav (Fig. 1B). Phosphorylation of the EGFPvav
proteins on tyrosine residues was con¢rmed by Western blot-
ting employing a speci¢c monoclonal antibody (not shown).
The distribution of Vav was analyzed by direct £uorescence
microscopy. As shown in Fig. 2, full length Vav (EGFPvav 1^
845) was distributed throughout the cytoplasm but excluded
from the nucleus. A similar di¡use cytoplasmic localization
was observed for the construct EGFPvav 143^845, lacking
the CH domain. By contrast, the two C-terminal deletion
mutants EGFPvav 1^595 and in particular EGFPvav 143^
595, localized to the nucleus. Confocal microscopy con¢rmed
the presence of EGFP £uorescence inside the nucleus (data
not shown). Thus, deletion of the carboxy-terminal SH3-SH2-
SH3 domain caused the translocation of Vav into the nucleus,
while deletion of the CH domain had no detectable e¡ect on
the localization of EGFPvav constructs. Identical localization
patterns were obtained with untagged versions of either full
length or N-terminally truncated Vav transiently transfected
into NIH 3T3 cells and visualized by indirect £uorescence
microscopy using a polyclonal Vav antibody (not shown).
Transient transfection of the construct EGFPvav 1^143 com-
prising the amino-terminus of Vav including the CH domain
into NIH 3T3 ¢broblasts revealed a spotty distribution along
the plasma membrane and in the cytoplasm (Fig. 2E). A sim-
ilar pattern was obtained with the isolated CH domain of
calponin h1 (Fig. 2F).
Vav is suspected to directly activate RhoA in addition to
Rac1 [7]. Therefore, we next compared the e¡ect of EGFPvav
overexpression on the organization of the stress ¢ber actin
cytoskeleton in cultured cells. In stable NIH 3T3 cell lines
expressing EGFPvav 1^845 the organization of the actin cy-
toskeleton was unaltered (Fig. 3A,B). CH domain-depleted
EGFPvav 143^845, in contrast, induced a characteristic par-
allel bundling of stress ¢bers (Fig. 3C,D). In stable cell lines
expressing comparable levels of the construct EGFPvav 143^
Fig. 2. Subcellular localization of EGFPvav constructs. Full length EGFPvav 1^845 (A) and EGFPvav 143^845 (B) localize throughout the cy-
toplasm of stable NIH 3T3 cells. Deletion of the C-terminal SH domains causes partial translocation of EGFPvav 1^595 to the nucleus with
residual £uorescent signal in the cytoplasm (C). The double truncation EGFPvav 143^595 localizes almost exclusively inside the nucleus (D).
Isolated CH domains of Vav (E) and h1 calponin (F) transiently transfected into NIH 3T3 cells are concentrated in spots distributed at the
plasma membrane and in the cytoplasm. All direct EGFP £uorescence.
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595 which shows an intense nuclear localization only marginal
stress ¢ber bundling was observed (not shown). Thus, the
bundling e¡ects required the cytoplasmic distribution of the
expressed transgene. Notably, forced expression of the same
construct in transiently transfected NIH 3T3 cells correlated
with a signi¢cantly increased EGFP £uorescence present in
the cytoplasm and lead to the induction of stress ¢ber bun-
dles, similar to those observed with the EGFPvav 143^845
construct (not shown). No signi¢cant colocalization of either
EGFPvav construct with these stress ¢ber arrays, however,
was observed.
When the stable NIH 3T3 clonal cell lines were treated with
5 WM cytochalasin B (Fig. 4A^D) or 200 nM latrunculin B
(Fig. 4E^H) for 30 min prior to ¢xation with 4% PFA, the
actin stress ¢ber arrays induced by EGFPvav 143^845 were
found resistant to actin depolymerization caused by either of
the two toxins (Fig. 4C,D,G,H). By contrast, the actin stress
¢bers of EGFPvav 1^845 expressing cells were sensitive to
both cytochalasin B (Fig. 4A,B) and latrunculin B (Fig.
4E,F). Double immuno£uorescence staining further revealed
that cells expressing low levels of EGFPvav 143^845 were as
sensitive to the action of the toxins as untransfected wild type
or EGFP control cells (not shown).
A possible mechanism for the activation of vav’s oncogenic
potential is the abolition of actin association of the oncopro-
tein upon disruption of its CH domain [35]. To further test
this hypothesis we extracted stably or transiently transfected
mouse NIH 3T3 and rat embryo ¢broblast (REF 52) cells in
the presence or absence of Triton X-100 and varying concen-
trations of KCl. In the absence of detergent, only a small
fraction of the EGFPvav protein was extracted from the cells
in the presence of either 10 or 100 mM KCl (Fig. 5, upper
panel). Addition of 0.5% Triton X-100 to the extraction bu¡er
led to the quantitative extraction of full length EGFPvav 1^
845, but was ine¡ective in solubilizing the CH domain-de-
pleted EGFPvav 143^845 mutant. Increasing the ionic
strength from 10 to 100 mM KCl had only a moderate e¡ect
on the extraction of EGFPvav 1^845, but e¡ectively reduced
the amount of EGFPvav 143^845 in the pellet by 50%.
4. Discussion
Rho family GTPases are known to modulate the arrange-
ment of F-actin structures [2,36] and their activity is in turn
regulated by a variety of GAPs and GEFs, acting as molec-
ular on and o¡ switches [27]. Precise cellular localization is an
essential prerequisite for signal transduction molecules to di-
rect their activities to other downstream targets. Thus, the
identi¢cation of a single CH domain in two GTPase regula-
tors, namely the Cdc42 GAP, IQGAP [37], and the Rac1
GEF, Vav [15], has evoked ideas about a possible interaction
of these upstream e¡ectors with actin [16,38,39] potentially
providing a direct link for signalling events to the actin cyto-
skeleton [26]. As a consequence of the above it has been
suggested further that the activation of Vav’s oncogenic
potential, mediated through activation of Rac and Rho is a
Fig. 3. Bundling of actin stress ¢bers by EGFPvav 143^845 in stable clonal lines of NIH 3T3 ¢broblasts. Cells expressing EGFPvav 143^845
show increased parallel bundling of the stress ¢bers which traverse the cell.
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result of inappropriate cellular localization caused by the loss
of the actin binding CH domain [14].
Fusion to EGFP did not compromise the localization of the
Vav constructs used. The distribution of full length and trun-
cated EGFPvav was similar to that of the untagged Vav coun-
terparts (data not shown) or that reported previously for HA-
[40] myc- [8] or T7- [41] tagged Vav. For both EGFPvav 1^
845 and EGFPvav 143^845 we observed a di¡use localization
in the cytoplasm and along the plasma membrane. We failed,
however, to detect any speci¢c enrichment along stress ¢bers
or in lamellipodia. Likewise, a construct comprising the iso-
lated CH domain of Vav transiently transfected into NIH 3T3
cells failed to associate with F-actin containing structures and
the resulting, punctate localization pattern was similar to that
observed with isolated CH domains of SM22 or calponin [18]
indicating that the CH domain alone is ine¡ective in targeting
Vav to the actin cytoskeleton.
Analysis of the amino acid sequence of Vav has identi¢ed
two putative NLS in the C-terminal half of the molecule [35],
and Vav is translocated into the nucleus of prolactin-stimu-
Fig. 4. EGFPvav 143^845-induced actin bundles are resistant to cytochalasin B and latrunculin B. Cells were serum-starved for 24 h and incu-
bated with the indicated toxins for 30 min. Note the presence of actin stress ¢bers in cells expressing EGFPvav 143^845 (D,H). A,C,E,G:
EGFP £uorescence. B,D,F,H: Actin visualized with Alexa 568.
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lated Nb2 cells [42] and UT7 S cells [34]. Moreover, Vav has
been shown in vitro to associate with the nuclear protein KU-
70, a subunit of the DNA-dependent protein kinase, via its C-
terminal SH3 domain [34]. Finally, Bertagnolo and colleagues
[43] demonstrated the presence of tyrosine phosphorylated
Vav in the nuclear compartment of stimulated HL-60 granu-
locytes. Here we show that deletion of the C-terminal SH3-
SH2-SH3 domains in Vav causes translocation of the corre-
sponding constructs into the nucleus. While EGFPvav 1^595
is partly retained in the cytoplasm, the double truncation
EGFPvav 143^595 is almost entirely translocated to the nu-
cleus. This suggests that the C-terminal SH domains can reg-
ulate (or mask) the adjacent nuclear localization signals. From
our limited deletion studies we are, however, unable to deter-
mine if one or both of the two putative NLS are functional in
Vav. Site-directed mutagenesis of the NLS sequences should
help to delineate the residues involved in nuclear translocation
of Vav.
Deletion of the CH domain resulted in an increased resist-
ance to extraction of the EGFPvav 143^845 construct in the
presence of Triton X-100 and intermediate ionic strength.
Based on the proposed function of the CH domain as an F-
actin binding module we expected that deletion of this motif
would result in an increased solubility of the corresponding
fragment. Surprisingly, however, the opposite was the case.
We were also unable to detect co-localization of Vav with
actin stress ¢bers or the EGFPvav 143^845-induced parallel
F-actin sheets, arguing against a direct bundling e¡ect of Vav
through its localization on actin. The resistance of actin stress
¢ber arrays induced by EGFPvav 143^845 to actin depolyme-
rization by cytochalasin B and latrunculin B points towards
the recruitment of an actin cross linking or bundling protein
downstream of the Vav-activated Rac/Rho signalling path-
way. These toxins a¡ect actin depolymerization by inhibition
of ¢lament growth from the fast growing, barbed ends of the
¢laments or by reducing the supply of polymerizable mono-
meric G-actin [44^46]. The resistance of stress ¢bers to dis-
assembly may thus be due to a markedly reduced rate of actin
stress ¢ber turnover observed in the EGFPvav 143^845 cells.
In contrast to our data, Schuebel et al. [47] using a similar
approach, observed a disruption rather than an induction of
stress ¢bers in NIH 3T3 cells constitutively expressing a trun-
cated version of Vav (Vav v1^67). They, however, reported
the formation of abundant stress ¢bers in clones derived from
the same cell line but expressing the Vav-2 oncoprotein. In-
terestingly, transient transfections resulted in the stimulation
of lamellipodial activity at the expense of both ¢lopodial pro-
trusion and stress ¢ber formation for both Vav variants [47].
In our hands, such strong e¡ects as those leading to a partial
disruption of actin stress ¢bers were observed only in cells
with excessive EGFPvav expression. However, such cases
were rare and were therefore not considered in this study.
Closer control of the expression levels of Rho family GTPases
and of the various GAPs and GEFs may thus be required in
order to gain reproducible and reliable information about the
in vivo e¡ects of these signalling molecules. The EGFP-tagged
constructs presented here allow the simultaneous monitoring
of expression levels and will serve as valuable tools in future
studies using living cells.
In conclusion, we have presented evidence for a possible
direct activation of Rho by Vav and that this activity is en-
hanced by the removal of the CH domain-containing N-ter-
minus, and suggested that translocation of Vav into the nu-
cleus may be regulated by an interaction of the nuclear
localization signals with the C-terminal SH domains.
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